Tezepelumab Home Use Study

Phase 3

Completed

Conditions: Asthma

Interventions: Biological: Tezepelumab (AI)
Biological: Tezepelumab (APFS)

Registration Number: NCT03968978

Lead Sponsor: AstraZeneca

Brief Summary: This is a multicenter, randomized, open-label, parallel-group study designed to assess healthcare provider and subject/caregiver reported functionality and performance of a single-use accessorized pre-filled syringe (APFS) or autoinjector (AI) with a fixed 210 mg dose of tezepelumab administered subcutaneously in the clinic and in an at-home setting.

Detailed Description: The study will consist of a screening/run-in period of up to 2 weeks and a treatment period of 24 weeks, followed by a post-treatment follow-up period of 12 weeks. During the treatment period, one dose of 210 mg tezepelumab will be administered via a single-use APFS or AI subcutaneously (SC) every 4 weeks (Q4W) starting at Visit 2 (Week 0) until Visit 7 (Week 20). Subjects will be administered tezepelumab at the site during Visits 2 (Week 0), 3 (Week 4), 4 (Week 8) and 7 (Week 20). At-home administration of tezepelumab will occur during Visit 5 (Week 12) and Visit 6 (Week 16). Each device will be assessed separately using descriptive presentations.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 216

Inclusion Criteria

Male or female, age 12 to 80 years.
Documented physician-diagnosed asthma for at least 12 months.
Evidence of asthma as documented by post BD (albuterol/salbutamol) reversibility of FEV1 ≥ 12% AND ≥200 mL (15-60 min after administration of 4 puffs of albuterol/salbutamol), documented either: in the previous 12 months prior to V1, OR demonstrated at V1, V1A, or at V2.
Documented history of current treatment with medium- or high-dose ICS for at least 6 months and at least one additional asthma controller medication according to standard practice of care. ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily.
Morning pre-BD FEV1 of >50% predicted normal at Visit 1, Visit 1A, or Visit 2.

Exclusion Criteria

Clinically important pulmonary or systemic diseases other than asthma.
History of cancer except basal cell carcinoma, squamous cell carcinoma, or in situ carcinoma of the cervix within 12 months prior to Visit 1.
Acute upper or lower respiratory infection requiring antibiotics or antiviral medications finalized <2 weeks before Visit 1 or during screening/run-in period.
A helminth parasitic infection diagnosed within 6 months that is untreated or is unresponsive to the standard of care.
Smoking history of ≥10 pack years, (includes vaping and e-cigarettes)
History of chronic alcohol or drug abuse.
Tuberculosis requiring treatment within 12 months prior to V1.
History of HIV, Hepatitis B or Hepatitis C.
Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives (whichever is longer) prior to visit 1 or receipt of any investigational non-biologic agent within 30 days or 5 half-lives.
Bronchial thermoplasty in 24 months prior to V1.
Anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) to any biologic therapy.
Evidence of active liver disease (e.g. jaundice, AST, ALT or ALP >2 times upper limit of normal), ongoing liver disease or inexplicably elevated liver chemistry values.
Pregnant, breastfeeding or lactating women.
Non-leukocyte depleted whole blood transfusion in 120 days prior to visit 1.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tezepelumab (AI)	Tezepelumab (AI)	Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
Tezepelumab (APFS)	Tezepelumab (APFS)	Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).

Primary Outcome Measures

Name	Time	Method
Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type	Week 0, Week 4, Week 8, Week 12, Week 16, Week 20	Successful administration is defined as an injection completed, based on a used/returned (HCP or subject/caregiver) answer of YES to all 5 questions in the administration questionnaire, and satisfactory in vitro evaluation of returned/evaluated devices.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score	Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24	The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.
Proportions of Used/Returned Devices That Pass Functional Tests and Visual Inspection and Showed no Evidence of Malfunction	Week 0, Week 4, Week 8, Week 12, Week 16, Week 20	Devices that passed functional tests and visual inspection and showed no evidence of malfunction will be evaluated as functional. Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.
Serum Trough Concentrations	Baseline (Week 0), Week 4, Week 20 and Week 24 (EOT)	PK serum samples were collected pre-dose on dosing visits
Proportions of Devices That Have Been Reported as Malfunctioning (Product Complaints)	Week 0, Week 4, Week 8, Week 12, Week 16, Week 20	Performance is measured by the proportion of APFS or AI devices that have been reported as malfunctioning (i.e. via Product Complaints). Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.
Anti-drug Antibodies (ADA)	Pre-treatment on dosing days until end of follow-up (Week 36) per protocol	Anti-drug antibodies (ADA) responses at baseline and/or post baseline. Treatment-induced ADA positive is defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive is defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following IP administration. Treatment-emergent ADA (TE-ADA) positive is defined as either treatment-induced ADA positive or treatment-boosted ADA positive. ADA incidence is the proportion of TE-ADA positive subjects in a population. Persistently positive is defined as ADA positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive